


Appl. No. 10/775,405  
 Amdt. dated January 24, 2006  
 Reply to Office Action of November 11, 2005

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim 1 (Currently Amended) A compound of the formula:



in which;

- a[.] M is NZ-OF-Θ;
- b[.] Z is represented by H or C<sub>1</sub>-C<sub>4</sub> alkyl;
- c[.] R<sup>1</sup> is represented by hydrogen, (C<sub>1</sub>-C<sub>2</sub>)alkyl, optionally substituted with one or more halogens, or (C<sub>1</sub>-C<sub>2</sub>)alkoxy, optionally substituted with one or more halogens;
- d[.] R<sup>2</sup> is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, (C<sub>2</sub>-

Appl. No. 10/775,405

Amdt. dated January 24, 2006

Reply to Office Action of November 11, 2005

$C_4$ alkynyl,  $(C_1-C_4)$ alkoxy,  $(C_1-C_2)$ alkyl substituted with one or more halogens,

$(C_1-C_2)$ alkoxy substituted with one or more halogens,  $SR^4$ , and  $NR^4R^5$ ;

e[.] X is represented by O or S;

f[.] A is represented by hydrogen,  $(C_1-C_8)$ alkyl,  $(C_2-C_8)$ alkenyl,  $(C_2-C_8)$ alkynyl, -

$[CH_2]_m-D-[CH_2]_n-(CH_3)$ ,  $-[CH_2]_mC(O)OR^4$ ,  $-[CH_2]_mC(O)R^4$ ,  $-[CH_2]_m$

$C(O)NR^4R^5$ , or  $(CH_2)_n-R^3-R^6$ ;

g[.] m is an integer selected from 1 to 8;

h[.] n is an integer from 0 to 8;

i[.] D is represented by O or S;

j[.]  $R^3$  is represented by optionally substituted phenyl, optionally substituted naphthyl,

$C_3-C_8$  cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;

k[.]  $R^4$  and  $R^5$  are each independently represented by hydrogen,  $(C_1-C_4)$ alkyl,

optionally substituted benzyl or optionally substituted phenyl, and;

l[.]  $R^6$  is absent, or is represented by a substituent selected from the group consisting

of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted phenoxy,  $C_3-C_8$ cycloalkyl, optionally substituted heterocyclic, and optionally substituted heteroaryl[.],

or a pharmaceutically acceptable salt thereof.

Claim 2. (original) The compound according to claim 1 in which  $NC(X)N-A$  is bonded to the para-position of the benzyl ring.

Claim 3. (original) The compound according to claim 1 in which  $NC(X)N-A$  is bonded to the ortho-position of the benzyl ring.

Claim 4. (original) The compound according to claim 2 in which X is represented by O.

Claim 5. (original) The compound according to claim 2 in which X is represented by S.

Claim 6. (original) The compound according to claim 3 in which X is represented by O.

Claim 7. (original) The compound according to claim 3 in which X is represented by S.

Appl. No. 10/775,405  
Amdt. dated January 24, 2006  
Reply to Office Action of November 11, 2005

Claim 8. (original) The compound according any one of claims 2, 3, 4, 5, 6 or 7 in which M is represented by NZ, in which Z is represented by hydrogen.

Claim 9. (original) The compound according to claim 8 in which A is represented by  $(CH_2)_n R^3 R^6$ , in which n is 0,  $R^6$  is absent and  $R^3$  is optionally substituted phenyl.

Claim 10. Cancelled.

Claim 11. (Currently Amended) A method for ~~treating the alleviating~~ a condition selected from the group consisting of alopecia, acne, oily skin, ~~prostate cancer, and~~ hirsutism, and ~~benign prostate hyperplasia,~~ comprising administering an effective amount of a compound according to Claim 1 to a patient in need thereof.

Claims 12 and 13 Cancelled.

Claim 14. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with one, or more, pharmaceutically acceptable excipients.

Claim 15. (Currently Amended) A topical pharmaceutical formulation comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with one, or more, pharmaceutically acceptable excipients suitable for dermal application.

Claim 16. (Cancelled)

Claim 17. (New) The compound according to claim 8 in which  $R^1$  is  $CF_3$  and  $R^2$  is absent.

Claim 18. (New) A compound according to claim 1 selected from the group consisting of:

1-ethyl-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]urea;

1-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]-3-phenylthiourea;

1-(4-methylbenzyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-(4-methoxy-2-methylphenyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]-3-phenethylthiourea;

1-(4-methoxyphenyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

{3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]ureido}acetic acid ethyl ester;

Appl. No. 10/775,405

Amdt. dated January 24, 2006

Reply to Office Action of November 11, 2005

1-(4-fluorophenyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-benzo[1,3]dioxol-5-ylmethyl-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-(3,5-dimethoxyphenyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]urea;

1-(4-methoxybenzyl)-3-[2-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-hexyl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]urea;

1-(4-methylbenzyl)-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-[2-(4-chlorophenyl)ethyl]-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]-3-phenethylthiourea;

1-Methyl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-(2,3-dimethoxybenzyl)-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]-3-(2-p-tolyloethyl)thiourea;

{3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]ureido}acetic acid ethyl ester;

1-allyl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-(2-morpholin-4-ylethyl)-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-naphthalen-1-yl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]urea;

1-benzo[1,3]dioxol-5-ylmethyl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea;

1-(4-methoxybenzyl)-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea; and

1-benzyl-3-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)phenyl]thiourea.